Biotech firm Actinogen Medical will use MindMate’s software in a pioneering clinical trial to test the effectiveness of a new drug for Alzheimer’s patients.

The drug, Xanamen, will be tested on patients recruited through MindMate. It is hoped the drug will inhibit the production of stress hormone cortisol in the brain, as evidence shows people with Alzheimer’s disease tend to have high cortisol levels.

MindMate is a free app developed for people with Alzheimer’s disease, brain injuries, dementia or other forms of cognitive decline. It is used by more than one million people around the world.

MindMate has offices in Glasgow and Los Angeles and earlier this year secured $2 million in funding from US investors.

Part of the trial will be based at the University of Edinburgh.

Susanne Mitschke, MindMate chief executive and co-founder, said: “This partnership is a fantastic opportunity to collaborate with one of the leading research organisations in Scotland and shows that Scotland is continuing to drive innovation also through world-leading biotech developments.”




Actinogen Medical